PUBLISHER: The Business Research Company | PRODUCT CODE: 1751007
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751007
Genomic urine testing is a non-invasive diagnostic approach that examines genetic material found in urine to identify specific biomarkers associated with various diseases, including cancer, infections, and genetic disorders. This method integrates genomics with advanced molecular techniques to detect mutations, gene expression profiles, or microbial DNA (deoxyribonucleic acid). Its main goal is early disease detection, ongoing monitoring, and the development of personalized treatment strategies for different health conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of genomic urine testing include DNA testing, RNA testing, microbial testing, and epigenetic testing. DNA (deoxyribonucleic acid) testing is a scientific technique used to study an individual's genetic makeup to determine biological relationships, verify identity, or uncover inherited health conditions. These tests are distributed through several channels, such as hospital pharmacies, mail-order pharmacies, and specialty pharmacies. Genomic urine tests are applied in areas such as cancer detection, infectious disease diagnosis, genetic disorder screening, and general health assessment. They cater to a broad spectrum of end users, including hospitals and clinics, diagnostic labs, research and academic institutions, and other healthcare providers.
The genomic urine testing market research report is one of a series of new reports from The Business Research Company that provides genomic urine testing market statistics, including the edge artificial intelligence integrated circuits industry global market size, regional shares, competitors with the genomic urine testing market share, detailed genomic urine testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic urine testing industry. This genomic urine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The genomic urine testing market size has grown rapidly in recent years. It will grow from$0.90 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historical period can be credited to the rising occurrence of urologic cancers, heightened demand for early cancer diagnosis, increased awareness of precision medicine, a growing number of genetic disorder cases, and expanding investments in biomarker research.
The genomic urine testing market size is expected to see rapid growth in the next few years. It will grow to$1.62 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecast period can be attributed to the rising adoption of liquid biopsy methods, an increasing emphasis on personalized medicine, a growing prevalence of chronic kidney diseases, heightened focus on at-home diagnostic testing solutions, and the expanding application of multi-omics approaches in urine-based testing. Key trends expected during the forecast period include the development of non-invasive diagnostic methods, advancement of high-sensitivity testing panels, integration of machine learning technologies, innovations in urine exosome isolation, and progress in single-cell urine sequencing.
The growing burden of chronic kidney disease is anticipated to drive the expansion of the genomic urine testing market in the coming years. Chronic kidney disease is a condition where the kidneys are damaged and unable to effectively filter blood, leading to an accumulation of waste and fluids in the body. This burden is increasing largely due to the rising prevalence of diabetes, as high blood sugar levels can damage kidney blood vessels, reducing their filtering capability. Genomic urine testing supports the management of chronic kidney disease by enabling early detection of genetic markers, which allows for timely intervention and personalized treatment plans. This approach improves patient outcomes by facilitating more accurate monitoring and slowing disease progression. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that mortality rates due to chronic kidney disease increased from 4.2% in 2021 to 6.2% in 2022. As a result, the escalating burden of chronic kidney disease is contributing to the growth of the genomic urine testing market.
Leading companies in the genomic urine testing industry are concentrating on innovative advancements, such as next-generation sequencing, to improve the precision, sensitivity, and early detection potential of non-invasive diagnostic tests for various illnesses. Next-generation sequencing is a sophisticated DNA sequencing method that facilitates fast, accurate, and large-scale analysis of genetic material by sequencing millions of DNA fragments simultaneously. For instance, in May 2023, Convergent Genomics Inc., a biotechnology company based in the United States, introduced the genomic urine test UroAmp. This test utilizes next-generation DNA sequencing to detect mutations in 60 genes linked to bladder cancer, allowing for early detection up to 12 years before symptoms appear. It offers comprehensive genetic data to support diagnosis, treatment planning, and recurrence monitoring, delivering greater accuracy than conventional techniques such as cytology and cystoscopy.
In September 2024, A. Menarini Diagnostics, an in-vitro diagnostics company headquartered in Italy, formed a partnership with Nucleix Ltd. The collaboration is focused on the commercialization and distribution of Bladder EpiCheck, a non-invasive genomic urine test designed for the early detection and monitoring of bladder and upper tract urothelial cancers throughout Europe. This initiative enhances the availability of advanced cancer diagnostic tools and aligns with clinical guidelines in Europe. Nucleix Ltd. is an Israel-based molecular diagnostics firm that specializes in epigenetic and genomic testing technologies.
Major players in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd.
North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genomic urine testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the genomic urine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The genomic urine testing market includes of revenues earned by entities by providing services such as early disease detection, genetic mutation analysis, cancer screening, infection diagnostics, personalized treatment planning, and monitoring of disease progression through non-invasive urine-based genomic profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Genomic Urine Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on genomic urine testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for genomic urine testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genomic urine testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.